Business, energy, technology, markets and global industry news from Business News Today

silmitasertib

PharmaDeviceNews silmitasertib
Senhwa Biosciences’ up to NT$500 million GEM share purchase agreement places its oncology pipeline, funding strategy and shareholder dilution under scrutiny. Representative image.
Pharma & Biotech

Senhwa’s NT$500m GEM deal sounds like fresh funding, but the structure is more complicated

Senhwa formalises a NT$500 million GEM share purchase pact, but direct funding, dilution and pipeline execution remain the decisive questions.

Read More
Pharma & Biotech

What the Senhwa Biosciences and CellType collaboration reveals about AI’s role in oncology pipelines

Senhwa Biosciences and CellType partner to advance silmitasertib with AI. Discover how the collaboration could reshape immunotherapy research.

Read More